NeyroblastGX is devoted to developing a highly sensitive Alzheimer’s blood-based biomarker diagnostic. Blood is a non-invasive method for detecting Alzheimer’s disease (AD). Our ADBD-testTM will determine AD biomarkers and distinguish between toxic proteins such as Abeta, tau, and their conformational dependent changes in specific blood fractions. This blood-based non-invasive biomarker diagnostics will replace invasive cerebrospinal fluid (CSF)-based biomarker detection, which requires painful lumbar puncture with a possible risk of infection. Our blood-based biomarkers only need a small amount of blood from a study subject as compared to other routine blood examinations. This method is very rapid, highly sensitive, and has high specificity to very precisely determine each of the AD biomarker proteins in specific blood fractions.


NeyroblastGX is currently working on a next generation theranostic product “DC-COV19” for COVID-19. Dendritic cells (DCs) are antigen presenting cells that act as a sentinel for any foreign invaders like SARS-CoV-2. DC-COV19 is a genetically engineered highly functional DC that not only can efficiently eliminate SARS-CoV-2 but also can eliminate any other harmful viruses from our immune system.


NeyroblastGX is aiming to provide organoid culture from human pluripotent stem cells for customers interested in screening drugs, cellular toxicity, and disease pathology. hORGanoid are custom made human organoids with a gene expression pattern similar to the mRNA levels of a tissue and organs such as the human lung, heart, or brain.


ImmuneCureTM is an oral supplement composed of a fine-tuned ratio of beneficial compounds we usually have in our daily diets. This oral supplement not only can protect our daily immunity but also can prevent secondary infection after recovery from viral or other
pathogen infections. ImmuneCureTM is the future R&D product of NeyroblastGX for inhibiting COVID-19 overactive immunity and post-COVID-19 immunosuppression by enhancing protective immunity.